The Threshold of Toxicological Concern (TTC) is an important risk assessment tool which establishes acceptable low-level exposure values to be applied to chemicals with limited toxicological data.
Dissolution Testing in Drug Product Development: Workshop Summary Report
This publication summarizes the proceedings and key outcomes of the first day (“Day 1”) of the 3-day workshop on “Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development.”
Physiologically Based Pharmacokinetic/ Pharmacodynamic Model for Caffeine Disposition in Pregnancy
Caffeine is the most consumed active stimulant. About 80% of pregnant women consume caffeine orally on daily basis. Many reports indicated consumption of >200 mg caffeine during pregnancy could increase the likelihood of miscarriage.
DILIsym® v8A Release Webinar
DILIsym is a mechanistic, predictive software tool focused on predicting and understand drug-induced liver injury across species. DILIsym version 8A is packed with exciting new features.
EDEn–Electroceutical Design Environment: Ion Channel Tissue Expression Database with Small Molecule Modulators
The emerging field of bioelectricity has revealed numerous new roles for ion channels beyond the nervous system, which can be exploited for applications in regenerative medicine.
PBPK Absorption Modeling: Establishing the In Vitro–In Vivo Link—Industry Perspective
The establishment of an in vitro–in vivo correlation (IVIVC) is considered the gold standard to establish in vivo relevance of a dissolution method and to utilize dissolution data in the context of regulatory bioequivalence questions...
DILIsym Awarded $1.5 Million Phase II NIH Grant
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months
Molecular Determinants of Cell Permeability Beyond the Rule of 5
Molecules that violate conventional guidelines for druglikeness—such as the Rule-of-5—are of increasing interest as chemical probes and drugs for intractable pharmacological targets.
Simulations Plus Releases DDDPlus™ Version 6
New models for in vitro systems lead to improved inputs for GastroPlus® simulations
DILIsym Services Inc. Initiates Development of IPFsym™
New idiopathic pulmonary fibrosis QSP platform to enable more efficient drug development
Simulations Plus Reports First Quarter FY2019 Financial Results
First quarter net revenues of $7.5 million reflecting 6.6% year over year growth. Board of Directors announces quarterly dividend of $0.06 per share
PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development
Prediction of the effect of food on drug’s pharmacokinetics using modeling and simulation could cause difficulties due to complex in vivo processes.
Support files in GastroPlus®
This video discusses support files in GastroPlus™.
DILIsym Services Inc. Releases DILIsym® Version 8A
Substantial update of liver safety software includes new science and practical extensions
Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results
Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST
Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen
Tamoxifen is an antiestrogen drug that is widely used in the adjuvant chemotherapy of estrogen receptor-α (ERα)-positive breast cancer.
A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme
The acceptance of foreign comparator products is the most limiting factor for the development and regulatory assessment of generic medicines marketed globally.
Model-Informed Drug Development for Malaria Therapeutics
Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries.